Efficacy of Pectoral Nerve Block for Breast Reduction Surgery

Sponsor
Antalya Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03857386
Collaborator
(none)
53
1
10
5.3

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the efficacy of PECS block applied to patients undergoing bilateral breast reduction surgery on postoperative analgesia compared to local infiltration anesthesia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: PECS group
  • Procedure: Control group

Detailed Description

Pectoral nerve block (PECS block) has been developed as an alternative to thoracic paravertebral and/or thoracic epidural blocks in recent years. It is frequently applied for postoperative analgesia especially in breast cancer surgery and subpectoral breast prosthesis.

Study Design

Study Type:
Observational
Actual Enrollment :
53 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Comparison of The Effects of Pectoral Nerve Block and Local Infiltration Anesthesia on Postoperative Analgesia for Breast Reduction Surgery
Actual Study Start Date :
Jul 1, 2017
Actual Primary Completion Date :
Mar 1, 2018
Actual Study Completion Date :
May 1, 2018

Arms and Interventions

Arm Intervention/Treatment
PECS group

Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach

Procedure: PECS group
Pecs block performed using ultrasound guidance
Other Names:
  • Regional anesthesia in breast surgery
  • Control group

    Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation

    Procedure: Control group
    Local infiltration anesthesia performed during the operation
    Other Names:
  • Regional anesthesia in breast surgery
  • Outcome Measures

    Primary Outcome Measures

    1. postoperative visual analog scale (VAS) score [postoperative 0, 1, 3, 6, 9, and 12 hours]

      Postoperative pain assessment will be performed using the VAS score (VAS 0 = no pain, VAS 10 = most severe pain possible). The VAS scores will be recorded at postoperative 0, 1, 3, 6, 9, and 12 hours.

    Secondary Outcome Measures

    1. analgesia consumption [12 hours]

      postoperative

    2. length of hospital [4 days]

      recorded at the following time after surgery

    3. analgesia consumption [during the surgery]

      intraoperative

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • American Society of Anesthesiology (ASA) I-II

    • body mass index (BMI) ≤40 kg/m2

    • elective bilateral breast reduction surgery

    Exclusion Criteria:
    • declining to give written informed consent

    • ASA III and above

    • under 18 years of age or over 65 years of age

    • history of allergy against to the local anesthetics,

    • controendication of peripheral block or local anesthetic infiltration (local infection, coagulopathy, etc.)

    • history of breast surgery

    • treatment due to psychiatric disorder

    • history of treatment for a chronic pain

    • history of nerve blocks in order to treat postoperative pain

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation Antalya Turkey 07100

    Sponsors and Collaborators

    • Antalya Training and Research Hospital

    Investigators

    • Principal Investigator: Arzu Karaveli, Netherlands: Ministry of Health, Welfare and Sports

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Arzu Karaveli, study director, Antalya Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT03857386
    Other Study ID Numbers:
    • 10/09
    First Posted:
    Feb 28, 2019
    Last Update Posted:
    Apr 30, 2019
    Last Verified:
    Apr 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Arzu Karaveli, study director, Antalya Training and Research Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 30, 2019